Who are Succinylcholine Chloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Succinylcholine, Nimbex, Nimbex, Zemuron, Mivacron, Tracrium Preservative Free.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/suxamethonium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Succinylcholine Chloride — Competitive Intelligence Brief

Succinylcholine Chloride (SUXAMETHONIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Depolarizing Neuromuscular Blocker. Area: Neuroscience.

marketed Depolarizing Neuromuscular Blocker Muscle-type nicotinic acetylcholine receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Succinylcholine Chloride (SUXAMETHONIUM) — Novartis. Succinylcholine Chloride works by mimicking the action of acetylcholine at the neuromuscular junction, causing a rapid depolarization of muscle fibers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Succinylcholine Chloride TARGET	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Succinylcholine	Succinylcholine	Charles University, Czech Republic	marketed		Muscle-type nicotinic acetylcholine receptor, Acetylcholinesterase
Nimbex	Cisatracurium Besylate	AbbVie	marketed	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Nimbex	CISATRACURIUM	AbbVie	marketed	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Zemuron	ROCURONIUM	Fresenius Kabi	marketed	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1994-01-01
Mivacron	MIVACURIUM	AbbVie	marketed	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1992-01-01
Tracrium Preservative Free	ATRACURIUM		marketed	Nondepolarizing Neuromuscular Blocker	Neuronal acetylcholine receptor subunit alpha-3	1983-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Depolarizing Neuromuscular Blocker class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Succinylcholine Chloride — Competitive Intelligence Brief. https://druglandscape.com/ci/suxamethonium. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab